{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:49:43Z","timestamp":1790628583008,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"EAsDEC Skills Award Program"},{"name":"Belfast Association for the Blind"},{"DOI":"10.13039\/501100000361","name":"Diabetes UK","doi-asserted-by":"publisher","award":["18\/0005791"],"award-info":[{"award-number":["18\/0005791"]}],"id":[{"id":"10.13039\/501100000361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/I026359\/1"],"award-info":[{"award-number":["BB\/I026359\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2022-138544OB-I00"],"award-info":[{"award-number":["PID2022-138544OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["ICI20\/00129"],"award-info":[{"award-number":["ICI20\/00129"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Impaired function of the retinal neurovascular unit (NVU) is an early event in diabetic retinopathy (DR). It has been previously shown that topical delivery of the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin can protect against diabetes-mediated dysfunction of the retinal NVU in the\n                    <jats:italic>db\/db<\/jats:italic>\n                    mouse. The aim of the present study was to examine whether sitagliptin could prevent the DR-like lesions within the NVU of the new non-diabetic model of DR, the\n                    <jats:italic>Trpv2<\/jats:italic>\n                    knockout rat (\n                    <jats:italic>Trpv2<\/jats:italic>\n                    <jats:sup>+\/\u2212<\/jats:sup>\n                    ). For that purpose, at 3 months of age,\n                    <jats:italic>Trpv2<\/jats:italic>\n                    <jats:sup>+\/\u2212<\/jats:sup>\n                    rats were topically treated twice daily for two weeks with sitagliptin or PBS-vehicle eyedrops.\n                    <jats:italic>Trpv2<\/jats:italic>\n                    <jats:sup>+\/+<\/jats:sup>\n                    rats treated with vehicle served as the control group. Body weight and glycemia were monitored. Optical coherence tomography recordings, fundus images and retinal samples were obtained to evaluate sitagliptin effects. The results revealed that sitagliptin eye drops had no effect on body weight or glycemia. Vehicle-treated\n                    <jats:italic>Trpv2<\/jats:italic>\n                    <jats:sup>+\/\u2212<\/jats:sup>\n                    rats exhibited retinal thinning and larger diameters of major retinal blood vessels, upregulation of inflammatory factors and oxidative markers, glial activation and formation of acellular capillaries. However, topical administration of sitagliptin significantly prevented all these abnormalities. In conclusion, sitagliptin eye drops exert a protective effect against DR-like lesions in\n                    <jats:italic>Trpv2<\/jats:italic>\n                    <jats:sup>+\/\u2212<\/jats:sup>\n                    rats. Our results suggest that sitagliptin eye drops carry significant potential to treat not only early-stages of DR but also other diseases with impairment of the NVU unrelated to diabetes.\n                  <\/jats:p>","DOI":"10.1186\/s12974-024-03283-5","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T06:32:40Z","timestamp":1732948360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Sitagliptin eye drops prevent the impairment of retinal neurovascular unit in the new Trpv2+\/\u2212 rat model"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-7576","authenticated-orcid":false,"given":"Hugo","family":"Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5178-5029","authenticated-orcid":false,"given":"Josy","family":"Augustine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9362-9267","authenticated-orcid":false,"given":"Burak M.","family":"Karan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3109-1721","authenticated-orcid":false,"given":"Cristina","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8647-9918","authenticated-orcid":false,"given":"Alan W.","family":"Stitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1543-2781","authenticated-orcid":false,"given":"Tim M.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0475-3096","authenticated-orcid":false,"given":"Rafael","family":"Sim\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,30]]},"reference":[{"key":"3283_CR1","doi-asserted-by":"publisher","first-page":"16012","DOI":"10.1038\/nrdp.2016.12","volume":"2","author":"TY Wong","year":"2016","unstructured":"Wong TY, Cheung CM, Larsen M, Sharma S, Sim\u00f3 R. Diabetic retinopathy. Nat Rev Dis Primers. 2016;2:16012. https:\/\/doi.org\/10.1038\/nrdp.2016.12.","journal-title":"Nat Rev Dis Primers"},{"issue":"14","key":"3283_CR2","doi-asserted-by":"publisher","first-page":"e93751","DOI":"10.1172\/jci.insight.93751","volume":"2","author":"EJ Duh","year":"2017","unstructured":"Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight. 2017;2(14):e93751. https:\/\/doi.org\/10.1172\/jci.insight.93751.","journal-title":"JCI Insight"},{"issue":"9","key":"3283_CR3","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1007\/s00125-018-4692-1","volume":"61","author":"R Sim\u00f3","year":"2018","unstructured":"Sim\u00f3 R, Stitt AW, Gardner TW. Neurodegeneration in diabetic retinopathy: does it really matter? Diabetologia. 2018;61(9):1902\u201312. https:\/\/doi.org\/10.1007\/s00125-018-4692-1.","journal-title":"Diabetologia"},{"issue":"9","key":"3283_CR4","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1007\/s00125-023-05940-5","volume":"66","author":"R Sim\u00f3","year":"2023","unstructured":"Sim\u00f3 R, Hern\u00e1ndez C. What else can we do to prevent diabetic retinopathy? Diabetologia. 2023;66(9):1614\u201321. https:\/\/doi.org\/10.1007\/s00125-023-05940-5.","journal-title":"Diabetologia"},{"issue":"1","key":"3283_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2337\/db15-0443","volume":"65","author":"C Hern\u00e1ndez","year":"2016","unstructured":"Hern\u00e1ndez C, Bogdanov P, Corraliza L, et al. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes. 2016;65(1):172\u201387. https:\/\/doi.org\/10.2337\/db15-0443.","journal-title":"Diabetes"},{"issue":"11","key":"3283_CR6","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1007\/s00125-017-4388-y","volume":"60","author":"C Hern\u00e1ndez","year":"2017","unstructured":"Hern\u00e1ndez C, Bogdanov P, Sol\u00e0-Adell C, et al. Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes. Diabetologia. 2017;60(11):2285\u201398. https:\/\/doi.org\/10.1007\/s00125-017-4388-y.","journal-title":"Diabetologia"},{"issue":"8","key":"3283_CR7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3390\/biomedicines9080926","volume":"9","author":"R Sim\u00f3","year":"2021","unstructured":"Sim\u00f3 R, Bogdanov P, Ramos H, Huerta J, Sim\u00f3-Servat O, Hern\u00e1ndez C. Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes. Biomedicines. 2021;9(8):926. https:\/\/doi.org\/10.3390\/biomedicines9080926.","journal-title":"Biomedicines"},{"issue":"2","key":"3283_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","volume":"42","author":"BA McLean","year":"2021","unstructured":"McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr Rev. 2021;42(2):101\u201332. https:\/\/doi.org\/10.1210\/endrev\/bnaa032.","journal-title":"Endocr Rev"},{"issue":"2","key":"3283_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/biomedicines10020465","volume":"10","author":"P Bogdanov","year":"2022","unstructured":"Bogdanov P, Ramos H, Valeri M, et al. Minimum effective dose of DPP-4 inhibitors for treating early stages of Diabetic Retinopathy in an experimental model. Biomedicines. 2022;10(2):465. https:\/\/doi.org\/10.3390\/biomedicines10020465.","journal-title":"Biomedicines"},{"issue":"12","key":"3283_CR10","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3390\/biomedicines9121772","volume":"9","author":"H Ramos","year":"2021","unstructured":"Ramos H, Bogdanov P, Sabater D, et al. Neuromodulation Induced by Sitagliptin: a New Strategy for Treating Diabetic Retinopathy. Biomedicines. 2021;9(12):1772. https:\/\/doi.org\/10.3390\/biomedicines9121772.","journal-title":"Biomedicines"},{"issue":"1","key":"3283_CR11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/ijms24010571","volume":"24","author":"H Ramos","year":"2022","unstructured":"Ramos H, Bogdanov P, Sim\u00f3 R, De\u00e0s-Just A, Hern\u00e1ndez C. Transcriptomic analysis reveals that retinal neuromodulation is a relevant mechanism in the neuroprotective effect of Sitagliptin in an experimental model of Diabetic Retinopathy. Int J Mol Sci. 2022;24(1):571. https:\/\/doi.org\/10.3390\/ijms24010571.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3283_CR12","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3390\/antiox11071418","volume":"11","author":"H Ramos","year":"2022","unstructured":"Ramos H, Bogdanov P, Huerta J, De\u00e0s-Just A, Hern\u00e1ndez C, Sim\u00f3 R. Antioxidant effects of DPP-4 inhibitors in early stages of Experimental Diabetic Retinopathy. Antioxid (Basel). 2022;11(7):1418. https:\/\/doi.org\/10.3390\/antiox11071418.","journal-title":"Antioxid (Basel)"},{"issue":"2","key":"3283_CR13","doi-asserted-by":"publisher","first-page":"e0212007","DOI":"10.1371\/journal.pone.0212007","volume":"14","author":"A Lampert","year":"2019","unstructured":"Lampert A, Bruckner T, Haefeli WE, Seidling HM. Improving eye-drop administration skills of patients - A multicenter parallel-group cluster-randomized controlled trial. PLoS ONE. 2019;14(2):e0212007. https:\/\/doi.org\/10.1371\/journal.pone.0212007.","journal-title":"PLoS ONE"},{"issue":"5","key":"3283_CR14","doi-asserted-by":"publisher","first-page":"640","DOI":"10.4093\/dmj.2018.0137","volume":"43","author":"YR Chung","year":"2019","unstructured":"Chung YR, Ha KH, Kim HC, Park SJ, Lee K, Kim DJ. Dipeptidyl Peptidase-4 inhibitors versus other antidiabetic drugs added to Metformin Monotherapy in Diabetic Retinopathy Progression: a Real World-based Cohort Study. Diabetes Metab J. 2019;43(5):640\u20138. https:\/\/doi.org\/10.4093\/dmj.2018.0137.","journal-title":"Diabetes Metab J"},{"key":"3283_CR15","doi-asserted-by":"publisher","first-page":"100596","DOI":"10.1016\/j.curtheres.2020.100596","volume":"93","author":"OM Taylor","year":"2020","unstructured":"Taylor OM, Lam C. The Effect of Dipeptidyl Peptidase-4 inhibitors on Macrovascular and Microvascular complications of Diabetes Mellitus: a systematic review. Curr Ther Res Clin Exp. 2020;93:100596. https:\/\/doi.org\/10.1016\/j.curtheres.2020.100596.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"5","key":"3283_CR16","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/dom.13232","volume":"20","author":"H Tang","year":"2018","unstructured":"Tang H, Li G, Zhao Y, et al. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: a network meta-analysis. Diabetes Obes Metab. 2018;20(5):1262\u201379. https:\/\/doi.org\/10.1111\/dom.13232.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"3283_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/bdd.662","volume":"30","author":"H Fuchs","year":"2009","unstructured":"Fuchs H, Binder R, Greischel A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos. 2009;30(5):229\u201340. https:\/\/doi.org\/10.1002\/bdd.662.","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"3283_CR18","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1124\/dmd.108.026088","volume":"37","author":"A Fura","year":"2009","unstructured":"Fura A, Khanna A, Vyas V, et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos. 2009;37(6):1164\u201371. https:\/\/doi.org\/10.1124\/dmd.108.026088.","journal-title":"Drug Metab Dispos"},{"issue":"18","key":"3283_CR19","doi-asserted-by":"publisher","first-page":"e155128","DOI":"10.1172\/jci.insight.155128","volume":"7","author":"M O\u2019Hare","year":"2022","unstructured":"O\u2019Hare M, Esquiva G, McGahon MK, et al. Loss of TRPV2-mediated blood flow autoregulation recapitulates diabetic retinopathy in rats. JCI Insight. 2022;7(18):e155128. https:\/\/doi.org\/10.1172\/jci.insight.155128.","journal-title":"JCI Insight"},{"issue":"1","key":"3283_CR20","doi-asserted-by":"publisher","first-page":"18401","DOI":"10.1038\/s41598-021-97651-3","volume":"11","author":"J Hanaguri","year":"2021","unstructured":"Hanaguri J, Yokota H, Watanabe M, et al. Retinal blood flow dysregulation precedes neural retinal dysfunction in type 2 diabetic mice. Sci Rep. 2021;11(1):18401. https:\/\/doi.org\/10.1038\/s41598-021-97651-3.","journal-title":"Sci Rep"},{"issue":"9","key":"3283_CR21","doi-asserted-by":"publisher","first-page":"dmm050174","DOI":"10.1242\/dmm.050174","volume":"16","author":"J Augustine","year":"2023","unstructured":"Augustine J, Pavlou S, Harkin K, Stitt AW, Xu H, Chen M. IL-33 regulates M\u00fcller cell-mediated retinal inflammation and neurodegeneration in diabetic retinopathy. Dis Model Mech. 2023;16(9):dmm050174. https:\/\/doi.org\/10.1242\/dmm.050174.","journal-title":"Dis Model Mech"},{"issue":"10","key":"3283_CR22","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/s41374-019-0264-3","volume":"99","author":"H Toh","year":"2019","unstructured":"Toh H, Smolentsev A, Bozadjian RV, et al. Vascular changes in diabetic retinopathy-a longitudinal study in the Nile rat. Lab Invest. 2019;99(10):1547\u201360. https:\/\/doi.org\/10.1038\/s41374-019-0264-3.","journal-title":"Lab Invest"},{"key":"3283_CR23","doi-asserted-by":"publisher","first-page":"732820","DOI":"10.3389\/fcell.2021.732820","volume":"9","author":"EC Kugler","year":"2021","unstructured":"Kugler EC, Greenwood J, MacDonald RB. The neuro-glial-vascular unit: the role of glia in neurovascular unit formation and dysfunction. Front Cell Dev Biol. 2021;9:732820. https:\/\/doi.org\/10.3389\/fcell.2021.732820.","journal-title":"Front Cell Dev Biol"},{"key":"3283_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1874364101307010004","volume":"7","author":"N Gupta","year":"2013","unstructured":"Gupta N, Mansoor S, Sharma A, et al. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013;7:4\u201310. https:\/\/doi.org\/10.2174\/1874364101307010004.","journal-title":"Open Ophthalmol J"},{"issue":"1","key":"3283_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40662-021-00239-1","volume":"8","author":"S Nian","year":"2021","unstructured":"Nian S, Lo ACY, Mi Y, Ren K, Yang D. Neurovascular unit in diabetic retinopathy: pathophysiological roles and potential therapeutical targets. Eye Vis (Lond). 2021;8(1):15. https:\/\/doi.org\/10.1186\/s40662-021-00239-1.","journal-title":"Eye Vis (Lond)"},{"issue":"9","key":"3283_CR26","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.bbadis.2016.05.024","volume":"1862","author":"AI Arroba","year":"2016","unstructured":"Arroba AI, Alcalde-Estevez E, Garc\u00eda-Ram\u00edrez M, et al. Modulation of microglia polarization dynamics during diabetic retinopathy in db\/db mice. Biochim Biophys Acta. 2016;1862(9):1663\u201374. https:\/\/doi.org\/10.1016\/j.bbadis.2016.05.024.","journal-title":"Biochim Biophys Acta"},{"key":"3283_CR27","doi-asserted-by":"publisher","first-page":"465694","DOI":"10.1155\/2014\/465694","volume":"2014","author":"AR Santiago","year":"2014","unstructured":"Santiago AR, Baptista FI, Santos PF, et al. Role of microglia adenosine A(2A) receptors in retinal and brain neurodegenerative diseases. Mediators Inflamm. 2014;2014:465694. https:\/\/doi.org\/10.1155\/2014\/465694.","journal-title":"Mediators Inflamm"},{"key":"3283_CR28","doi-asserted-by":"publisher","first-page":"659843","DOI":"10.3389\/fncel.2021.659843","volume":"15","author":"MA Dixon","year":"2021","unstructured":"Dixon MA, Greferath U, Fletcher EL, Jobling AI. The contribution of Microglia to the development and maturation of the Visual System. Front Cell Neurosci. 2021;15:659843. https:\/\/doi.org\/10.3389\/fncel.2021.659843.","journal-title":"Front Cell Neurosci"},{"key":"3283_CR29","doi-asserted-by":"publisher","first-page":"121931","DOI":"10.1016\/j.jchromb.2019.121931","volume":"1136","author":"C Guo","year":"2020","unstructured":"Guo C, Chen Q, Chen J, et al. 8-Hydroxyguanosine as a possible RNA oxidative modification marker in urine from colorectal cancer patients: evaluation by ultra performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1136:121931. https:\/\/doi.org\/10.1016\/j.jchromb.2019.121931.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"2","key":"3283_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2337\/db18-0682","volume":"68","author":"R Sim\u00f3","year":"2019","unstructured":"Sim\u00f3 R, Hern\u00e1ndez C, Porta M, et al. European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Effects of topically administered neuroprotective drugs in early stages of Diabetic Retinopathy: results of the EUROCONDOR Clinical Trial. Diabetes. 2019;68(2):457\u201363. https:\/\/doi.org\/10.2337\/db18-0682.","journal-title":"Diabetes"},{"issue":"8","key":"3283_CR31","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.3390\/jcm9082579","volume":"9","author":"C Hern\u00e1ndez","year":"2020","unstructured":"Hern\u00e1ndez C, Arroba AI, Bogdanov P, et al. Effect of Topical Administration of Somatostatin on retinal inflammation and neurodegeneration in an experimental model of diabetes. J Clin Med. 2020;9(8):2579. https:\/\/doi.org\/10.3390\/jcm9082579.","journal-title":"J Clin Med"},{"key":"3283_CR32","doi-asserted-by":"publisher","first-page":"1015522","DOI":"10.3389\/fphar.2022.1015522","volume":"13","author":"G Zerbini","year":"2022","unstructured":"Zerbini G, Maestroni S, Leocani L, et al. Topical nerve growth factor prevents neurodegenerative and vascular stages of diabetic retinopathy. Front Pharmacol. 2022;13:1015522. https:\/\/doi.org\/10.3389\/fphar.2022.1015522.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3283_CR33","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.2119\/molmed.2012.00008","volume":"18","author":"Y Liu","year":"2012","unstructured":"Liu Y, Leo LF, McGregor C, Grivitishvili A, Barnstable CJ, Tombran-Tink J. Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(akita) mice. Mol Med. 2012;18(1):1387\u2013401. https:\/\/doi.org\/10.2119\/molmed.2012.00008.","journal-title":"Mol Med"},{"key":"3283_CR34","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.biopha.2018.03.144","volume":"102","author":"A Gon\u00e7alves","year":"2018","unstructured":"Gon\u00e7alves A, Almeida L, Silva AP, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates retinal endothelial cell dysfunction triggered by inflammation. Biomed Pharmacother. 2018;102:833\u20138. https:\/\/doi.org\/10.1016\/j.biopha.2018.03.144.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3283_CR35","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1038\/s41598-023-30432-2","volume":"13","author":"E Borrelli","year":"2023","unstructured":"Borrelli E, Barresi C, Feo A, et al. Imaging biomarkers and clinical factors associated with the rate of progressive inner and outer retinal thinning in patients with diabetic macular edema. Sci Rep. 2023;13(1):3224. https:\/\/doi.org\/10.1038\/s41598-023-30432-2.","journal-title":"Sci Rep"},{"key":"3283_CR36","doi-asserted-by":"publisher","first-page":"801269","DOI":"10.1155\/2014\/801269","volume":"2014","author":"SZ Safi","year":"2014","unstructured":"Safi SZ, Qvist R, Kumar S, Batumalaie K, Ismail IS. Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets. Biomed Res Int. 2014;2014:801269. https:\/\/doi.org\/10.1155\/2014\/801269.","journal-title":"Biomed Res Int"},{"issue":"12","key":"3283_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11892-021-01428-x","volume":"21","author":"MM Sachdeva","year":"2021","unstructured":"Sachdeva MM. Retinal neurodegeneration in diabetes: an emerging Concept in Diabetic Retinopathy. Curr Diab Rep. 2021;21(12):65. https:\/\/doi.org\/10.1007\/s11892-021-01428-x.","journal-title":"Curr Diab Rep"},{"issue":"5","key":"3283_CR38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/eye.2016.13","volume":"30","author":"P Carpineto","year":"2016","unstructured":"Carpineto P, Toto L, Aloia R, et al. Neuroretinal alterations in the early stages of diabetic retinopathy in patients with type 2 diabetes mellitus. Eye (Lond). 2016;30(5):673\u20139. https:\/\/doi.org\/10.1038\/eye.2016.13.","journal-title":"Eye (Lond)"},{"issue":"6","key":"3283_CR39","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1167\/iovs.11-8997","volume":"53","author":"HW van Dijk","year":"2012","unstructured":"van Dijk HW, Verbraak FD, Kok PH, et al. Early neurodegeneration in the retina of type 2 diabetic patients. Invest Ophthalmol Vis Sci. 2012;53(6):2715\u20139. https:\/\/doi.org\/10.1167\/iovs.11-8997.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"3283_CR40","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1167\/iovs.13-13056","volume":"55","author":"A Nagata","year":"2014","unstructured":"Nagata A, Omachi K, Higashide T, et al. OCT evaluation of neuroprotective effects of tafluprost on retinal injury after intravitreal injection of endothelin-1 in the rat eye. Invest Ophthalmol Vis Sci. 2014;55(2):1040\u20137. https:\/\/doi.org\/10.1167\/iovs.13-13056.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3283_CR41","doi-asserted-by":"publisher","unstructured":"Li H, Zhang J, Lin L, Xu L. (2019) Vascular protection of DPP-4 inhibitors in retinal endothelial cells in in vitro culture. Int Immunopharmacol 2019 66:162\u2013168. https:\/\/doi.org\/10.1016\/j.intimp.2018.10.040","DOI":"10.1016\/j.intimp.2018.10.040"},{"issue":"1","key":"3283_CR42","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s00125-013-3093-8","volume":"57","author":"Z Xu","year":"2014","unstructured":"Xu Z, Wei Y, Gong J, et al. NRF2 plays a protective role in diabetic retinopathy in mice. Diabetologia. 2014;57(1):204\u201313. https:\/\/doi.org\/10.1007\/s00125-013-3093-8.","journal-title":"Diabetologia"},{"key":"3283_CR43","doi-asserted-by":"publisher","first-page":"105007","DOI":"10.1016\/j.neuint.2021.105007","volume":"145","author":"JS Albert-Garay","year":"2021","unstructured":"Albert-Garay JS, Riesgo-Escovar JR, S\u00e1nchez-Ch\u00e1vez G, Salceda R. Retinal Nrf2 expression in normal and early streptozotocin-diabetic rats. Neurochem Int. 2021;145:105007. https:\/\/doi.org\/10.1016\/j.neuint.2021.105007.","journal-title":"Neurochem Int"},{"key":"3283_CR44","doi-asserted-by":"publisher","first-page":"114799","DOI":"10.1016\/j.taap.2019.114799","volume":"384","author":"H Li","year":"2019","unstructured":"Li H, Seo MS, An JR, et al. Dipeptidyl peptidase-4 inhibitor sitagliptin induces vasorelaxation via the activation of Kv channels and PKA. Toxicol Appl Pharmacol. 2019;384:114799. https:\/\/doi.org\/10.1016\/j.taap.2019.114799.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"3283_CR45","doi-asserted-by":"publisher","first-page":"e003277","DOI":"10.1161\/JAHA.112.003277","volume":"2","author":"M Ayaori","year":"2013","unstructured":"Ayaori M, Iwakami N, Uto-Kondo H, et al. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc. 2013;2(1):e003277. https:\/\/doi.org\/10.1161\/JAHA.112.003277.","journal-title":"J Am Heart Assoc"},{"key":"3283_CR46","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.redox.2014.04.006","volume":"2","author":"RS Eshaq","year":"2014","unstructured":"Eshaq RS, Wright WS, Harris NR. Oxygen delivery, consumption, and conversion to reactive oxygen species in experimental models of diabetic retinopathy. Redox Biol. 2014;2:661\u20136. https:\/\/doi.org\/10.1016\/j.redox.2014.04.006.","journal-title":"Redox Biol"},{"issue":"4","key":"3283_CR47","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00417-016-3578-5","volume":"255","author":"X Ding","year":"2017","unstructured":"Ding X, Zhang M, Gu R, Xu G, Wu H. Activated microglia induce the production of reactive oxygen species and promote apoptosis of co-cultured retinal microvascular pericytes. Graefes Arch Clin Exp Ophthalmol. 2017;255(4):777\u201388. https:\/\/doi.org\/10.1007\/s00417-016-3578-5.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"3283_CR48","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3390\/antiox11040617","volume":"11","author":"R Carpi-Santos","year":"2022","unstructured":"Carpi-Santos R, de Melo Reis RA, Gomes FCA, Calaza KC. Contribution of M\u00fcller cells in the Diabetic Retinopathy Development: focus on oxidative stress and inflammation. Antioxid (Basel). 2022;11(4):617. https:\/\/doi.org\/10.3390\/antiox11040617.","journal-title":"Antioxid (Basel)"},{"issue":"14","key":"3283_CR49","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1097\/00001756-199709290-00012","volume":"8","author":"A Germer","year":"1997","unstructured":"Germer A, Jahnke C, Mack A, Enzmann V, Reichenbach A. Modification of glutamine synthetase expression by mammalian M\u00fcller (glial) cells in retinal organ cultures. NeuroReport. 1997;8(14):3067\u201372. https:\/\/doi.org\/10.1097\/00001756-199709290-00012.","journal-title":"NeuroReport"},{"issue":"8","key":"3283_CR50","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/02713683.2022.2055084","volume":"47","author":"B Li","year":"2022","unstructured":"Li B, Ning B, Yang F, Guo C. Nerve growth factor promotes retinal neurovascular unit repair: a review. Curr Eye Res. 2022;47(8):1095\u2013105. https:\/\/doi.org\/10.1080\/02713683.2022.2055084.","journal-title":"Curr Eye Res"},{"issue":"8","key":"3283_CR51","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3389\/fcell.2020.00452","volume":"16","author":"LK Wareham","year":"2020","unstructured":"Wareham LK, Calkins DJ. The neurovascular unit in Glaucomatous Neurodegeneration. Front Cell Dev Biol. 2020;16(8):452. https:\/\/doi.org\/10.3389\/fcell.2020.00452.","journal-title":"Front Cell Dev Biol"},{"key":"3283_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40478-021-01149-y","volume":"9","author":"F Xia","year":"2021","unstructured":"Xia F, Ha Y, Shi S, et al. Early alterations of neurovascular unit in the retina in mouse models of tauopathy. Acta Neuropathol Commun. 2021;9:51. https:\/\/doi.org\/10.1186\/s40478-021-01149-y.","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"3283_CR53","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3233\/JAD-121975","volume":"34","author":"T Moreno-Ramos","year":"2013","unstructured":"Moreno-Ramos T, Benito-Le\u00f3n J, Villarejo A, Bermejo-Pareja F. Retinal nerve fiber layer thinning in dementia associated with Parkinson\u2019s disease, dementia with Lewy bodies, and Alzheimer\u2019s disease. J Alzheimers Dis. 2013;34(3):659\u201364.","journal-title":"J Alzheimers Dis"},{"key":"3283_CR54","doi-asserted-by":"publisher","first-page":"255","DOI":"10.21037\/atm.2018.04.41","volume":"6","author":"E Angelopoulou","year":"2018","unstructured":"Angelopoulou E, Piperi C. DPP-4 inhibitors: a promising therapeutic approach against Alzheimer\u2019s disease. Ann Transl Med. 2018;6:255\u2013255. https:\/\/doi.org\/10.21037\/atm.2018.04.41.","journal-title":"Ann Transl Med"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-024-03283-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-024-03283-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-024-03283-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T07:02:17Z","timestamp":1732950137000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-024-03283-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3283"],"URL":"https:\/\/doi.org\/10.1186\/s12974-024-03283-5","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,30]]},"assertion":[{"value":"15 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments were approved by the Animal Welfare Ethical Review Body (AWERB) of Queen\u2019s University Belfast. The protocol complied with the UK Home Office Animals (Scientific Procedures) Act 1986 (project license, PPL2888) and the Association for Research in Vision and Ophthalmology (ARVO) statement for the use of animals in ophthalmology and vision research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Two of the authors (Cristina Hern\u00e1ndez and Rafael Sim\u00f3) are inventors of the patent PCT\/EP2017\/060234, which is related to use of dipeptidyl peptidase-4 inhibitors (sitagliptin) for topical eye treatment of retinal neurodegenerative diseases.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"312"}}